- Home
- RARE vs TENB Comparison
RARE vs TENB Comparison
Compare RARE & TENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- TENB
- Stock Information
- Founded
- RARE 2010
- TENB 2002
- Country
- RARE United States
- TENB United States
- Employees
- RARE N/A
- TENB N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- TENB Computer Software: Prepackaged Software
- Sector
- RARE Health Care
- TENB Technology
- Exchange
- RARE Nasdaq
- TENB Nasdaq
- Market Cap
- RARE 5.2B
- TENB 4.9B
- IPO Year
- RARE 2014
- TENB 2018
- Fundamental
- Price
- RARE $40.89
- TENB $41.06
- Analyst Decision
- RARE Strong Buy
- TENB Buy
- Analyst Count
- RARE 15
- TENB 17
- Target Price
- RARE $92.00
- TENB $50.13
- AVG Volume (30 Days)
- RARE 1.0M
- TENB 890.2K
- Earning Date
- RARE 02-13-2025
- TENB 02-05-2025
- Dividend Yield
- RARE N/A
- TENB N/A
- EPS Growth
- RARE N/A
- TENB N/A
- EPS
- RARE N/A
- TENB N/A
- Revenue
- RARE $522,745,000.00
- TENB $877,596,000.00
- Revenue This Year
- RARE $26.70
- TENB $14.43
- Revenue Next Year
- RARE $19.02
- TENB $9.64
- P/E Ratio
- RARE N/A
- TENB N/A
- Revenue Growth
- RARE 27.44
- TENB 13.97
- 52 Week Low
- RARE $37.02
- TENB $35.25
- 52 Week High
- RARE $60.37
- TENB $53.50
- Technical
- Relative Strength Index (RSI)
- RARE 40.43
- TENB 53.06
- Support Level
- RARE $39.99
- TENB $37.78
- Resistance Level
- RARE $44.52
- TENB $43.36
- Average True Range (ATR)
- RARE 2.18
- TENB 1.20
- MACD
- RARE -0.03
- TENB 0.29
- Stochastic Oscillator
- RARE 17.75
- TENB 58.78
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.